Organization: Alnylam Pharmaceuticals Inc

Inex inks deal with Alnylam for RNAi

Vancouver’s Inex Pharmaceuticals Corp has granted an exclusive worldwide license to Alnylam Pharmaceuticals Inc, Cambridge MA, for its liposomal delivery formulation technology for the commercialization of RNA Interference (RNAi) therapeutics. Inex will receive US$8 million in Alnylam cash or stock at Anlylam’s option and three InterfeRx licence options to develop RNAi therapeutics. In addition, Anlylam…